摘要
目的评价改良FOLFOX方案联合介入治疗进展期胃癌的疗效与安全性。方法34例进展期胃癌患者接受改良FOLFOX方案联合介入治疗,每4～5周重复1次,直到出现疾病进展、不能接受的毒性、或者患者选择终止治疗结束,平均7个疗程。不良反应按照NCI毒性标准记录,数据经SPSS15.0统计软件采用Kaplan-Meier生存分析。结果所有患者都能耐受治疗,平均随访17个月,最长随访时间为32个月。CR 4例,PR 20例,NC 6例和PD 4例,RR 70.6%。中位生存期18个月,1年、2年、32个月累积生存率分别为76.5%,33.1%,12.5%。NCI 1～2级不良反应包括:白细胞减少(31.9%),血小板减少(11.8%),贫血(11.8%),恶心,呕吐(41.2%),腹泻(29.4%),ALT升高(5.9%),脱发(64.7%),周围神经炎(11.8%),NCI 3～4级不良反应包括恶心、呕吐(47.1%),腹泻(11.8%)。4例出现3级ALT升高。无一例患者发生与治疗相关的患者死亡。结论改良FOLFOX方案联合介入治疗进展期胃癌疗效较高,不良反应轻,因而相当安全。
Objective To evaluate the efficacy and safety of modified Folfox regimen in combination with interventional therapy for patients with advanced gastric cancer. Methods Thirty-four patients were treated with modified Folfox regimen in combination with interventional therapy which was given at intervals of 4 or 5 weeks until the disease became worse, or the patient could not tolerate the drug toxicity, or the patient decided to stop the treatment. On an average, each patient received 7 therapeutic courses. Response to treatment and toxicity reaction to the drug were recorded according to NCI toxicity criteria. All data were analyzed by using Kaplan-Meier method with SPSS software （version 15.0, Chicago, IL, USA）. Results All patients tolerated the toxicity and treatment. The mean follow-up period was 17 months, with the longest period being of 32 months. Of 34 patients, complete remission was seen in 4 （11.8%）, partial remission in 20 （58.8%）, stable condition in 6 （17.6%） and deterioration in 4 （11.8%）. The overall response rate was 70.6%. The cumulated survival rate at 12, 24 and 32 months was 76.5%, 33.1% and 12.5% respectively, with a median survival time of 18 months. NCI grade 1 or 2 toxicities occurred, including alopecia （64.7%）, peripheral nenritis （11.8%）, anemia （11.8%）, leneopenia （31.9%）, diarrhea （29.4%）, stomatitis （23.5%）, thrombocytopenia （11.8%） and elevated ALT （5.9%）. Grade 3 or 4 occurred in 47.1% and 11.8% of patients respectively, which included nausea, vomiting and diarrhea. Four patients developed grade 3 ALT elevation. No treatment-related death occurred. Conclusion Modified Folfox regimen in combination with interventional therapy is a safe and effective treatment for advanced gastric cancer with fewer adverse effects. （J Intervent Radiol, 2009, 18： 759-762）
出处
《介入放射学杂志》
CSCD
北大核心
2009年第10期759-762,共4页
Journal of Interventional Radiology
基金
国家自然科学基金资助项目(30870689)
